These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
508 related articles for article (PubMed ID: 34095761)
61. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms. Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375 [TBL] [Abstract][Full Text] [Related]
62. Calreticulin mutations in myeloproliferative neoplasms. Lavi N Rambam Maimonides Med J; 2014 Oct; 5(4):e0035. PubMed ID: 25386351 [TBL] [Abstract][Full Text] [Related]
63. Peptide nucleic acid probe-based fluorescence melting curve analysis for rapid screening of common JAK2, MPL, and CALR mutations. Park J; Song M; Jang W; Chae H; Lee GD; Kim K; Park H; Kim M; Kim Y Clin Chim Acta; 2017 Feb; 465():82-90. PubMed ID: 27939919 [TBL] [Abstract][Full Text] [Related]
64. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950 [TBL] [Abstract][Full Text] [Related]
66. Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. Kjær L Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32731609 [TBL] [Abstract][Full Text] [Related]
67. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359 [TBL] [Abstract][Full Text] [Related]
68. Myeloproliferative neoplasms: Current molecular biology and genetics. Saeidi K Crit Rev Oncol Hematol; 2016 Feb; 98():375-89. PubMed ID: 26697989 [TBL] [Abstract][Full Text] [Related]
69. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952 [TBL] [Abstract][Full Text] [Related]
71. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Bellucci S; Michiels JJ Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614 [TBL] [Abstract][Full Text] [Related]
72. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. Kandarpa M; Wu YM; Robinson D; Burke PW; Chinnaiyan AM; Talpaz M Am J Hematol; 2017 Jun; 92(6):555-561. PubMed ID: 28335073 [TBL] [Abstract][Full Text] [Related]
73. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms. Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562 [TBL] [Abstract][Full Text] [Related]
74. Disease modifying agents of myeloproliferative neoplasms: a review. Lee SE Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032 [TBL] [Abstract][Full Text] [Related]
75. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873 [TBL] [Abstract][Full Text] [Related]
77. Mutant Calreticulin in the Myeloproliferative Neoplasms. Prins D; González Arias C; Klampfl T; Grinfeld J; Green AR Hemasphere; 2020 Feb; 4(1):e333. PubMed ID: 32382708 [TBL] [Abstract][Full Text] [Related]
78. Lab tests for MPN. Moncada A; Pancrazzi A Int Rev Cell Mol Biol; 2022; 366():187-220. PubMed ID: 35153004 [TBL] [Abstract][Full Text] [Related]
79. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. Jia R; Kralovics R Int J Hematol; 2020 Feb; 111(2):182-191. PubMed ID: 31741139 [TBL] [Abstract][Full Text] [Related]